November 7, 2018

Secretary of Health Alex Azar  
U. S. Department of Health and Human Services  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Dear Secretary Azar,

We are writing as current and former members of the Chronic Fatigue Syndrome Advisory Committee (CFSAC), as biomedical researchers and clinicians with expertise in the disease Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and as ME/CFS patient organizations to voice our concerns with HHS’s decision to disband the CFSAC. We are calling for CFSAC to be immediately reinstated.

The 2015 report by the National Academy of Medicine (NAM) stated that ME/CFS “is a serious, chronic, complex, and multisystem disease that frequently and dramatically limits the activities of affected patients.” NAM noted that ME/CFS affects 1-2.5M Americans of all genders, ages, races, and ethnic groups. It results in more functional impairment than a number of other chronic diseases with many patients unable to work and costs the economy $17-24B annually in direct medical expenditures and lost productivity. NAM found, “remarkably little research funding,” a “paucity of research” outside the fields of psychiatry and psychology, and a healthcare profession who have been persuaded that ME/CFS is a psychological problem. Further, NAM also notes a lack of diagnostics and FDA-approved treatments and a medical community that views the disease negatively, expresses hostility and disbelief to patients, and recommends treatments that can exacerbate their symptoms. This situation has persisted for the last three decades.

During its 15-year tenure, CFSAC repeatedly recommended that HHS address these issues. CFSAC’s concerns were reiterated in HHS’s own reports and in the NAM report. But the vast majority of those recommendations were not enacted by HHS and little changed.

Following the 2015 NAM report, co-sponsored by HHS and the Social Security Administration, and NIH’s 2015 Pathways to Prevention report, the situation is just beginning to improve. NIH has begun to invest in research programs. The CDC has updated its website with more accurate information. A few major academic centers have begun to research the disease.

But funding still remains far below that of other similarly disabling diseases. The breadth and volume of research being conducted lags far behind that necessary to deliver urgently needed diagnostics and treatments. Little is known about the natural history of the disease and nothing about how to prevent it. There exist only a dozen or so clinical experts nationwide, a number of whom are reaching retirement age while other medical
providers still either doubt the disease is real or lack the knowledge to provide appropriate patient-care. Patients struggle to get even the most basic treatment.

These outstanding needs – “research on diagnosis, treatment and management of ME/CFS”, “inform…health care professionals”, “partnerships to improve the quality of life of ME/CFS patients” – comprise the Duties outlined in CFSAC’s Charter. CFSAC’s work is not done. The very recent progress is still precarious, tentative, and has not yet made a difference in patient care or outcomes.

In the last two years, CFSAC has begun to establish productive, collaborative partnerships across the ME/CFS community, HHS agencies, and other Departments including the Social Security Administration, and the recently added Department of Defense and the Veterans’ Administration. While not a member, the Department of Education was also an active participant. CFSAC’s current workgroups had been focused on medical education, engaging pharmaceutical companies to stimulate treatment trials, and promoting awareness and education in schools. These efforts were all cut short when CFSAC was dissolved.

There is no other entity in the U.S. capable of advancing such broad-based engagement and collaborations across such diverse areas of need. Given CFSAC’s unique role and the magnitude and urgency of persisting needs, we believe it is shortsighted to dissolve CFSAC at this critical time.

We respectfully request CFSAC’s immediate reinstatement with the full constituency that existed when it was disbanded. We look forward to your response.

Respectfully,

Current CFSAC members (As of September 2018)
  
  Dr. Faith Newton, (CFSAC Chair)
  Professor of Education
  Delaware State University
  Dover, Delaware
  
  Lucinda Bateman, MD
  Medical Director
  Bateman Horne Center
  Salt Lake City, Utah
  
  Alisa Erika Koch, MD, PhD
  
  Jose G. Montoya, MD, FACP, FIDSA
  Professor of Medicine
  Division of Infectious Diseases and Geographic Medicine
Stanford University School of Medicine
Stanford, California

Donna Pearson

Amrit Shahzad, MBBS, MBA
Ben HsuBorger
CFSAC Liaison Member for MEAction

Courtney Miller
CFSAC Liaison Member for Simmaron Research

Terri L. Wilder, MSW
CFSAC Liaison Member for MEAction

Leah Williams, PhD
CFSAC Liaison Member for Massachusetts ME/CFS & FM Association

Former CFSAC Members
Dane Cook
Professor
University of Wisconsin – Madison
Department of Kinesiology
Madison, Wisconsin

Kenneth J. Friedman, PhD
Associate Professor of Physiology and Pharmacology (retired)
New Jersey Medical School
University of Medicine and Dentistry of New Jersey
Newark, New Jersey

Carol Head
CFSAC Liaison Member for Solve ME/CFS Initiative
President, Solve ME/CFS Initiative
Los Angeles, California

Leonard A. Jason, PhD
Professor of Psychology
DePaul University
Chicago, Illinois

Nancy Klimas MD
Director, Institute for Neuro-Immune Medicine
Nova Southeastern University
Director, Miami VA Medical Center GWI and CFS/ME Program
Miami, Florida

Steven P. Krafchick MPH, JD
Treasurer, International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
Private Law Practice
Legal Services for Injured and Disabled People
Seattle, Washington

Charles W. Lapp, MD
Medical Director
Hunter-Hopkins Center, PLLC
Charlotte, North Carolina

Susan Levine, MD
Researcher and Clinician, Private Practice
New York, New York
Visiting Fellow, Cornell University
Ithaca, New York

James M. Oleske, MD, MPH
François-Xavier Bagnoud Distinguished Professor of Pediatrics
Senator of RBHS Research Centers, Bureaus, and Institutes
Director, Division of Pediatrics Allergy, Immunology & Infectious Diseases
Department of Pediatrics, Rutgers - New Jersey Medical School, Newark, New Jersey

Christopher R. Snell, PhD
Scientific Director
WorkWell Foundation
Ripon, California

Staci Stevens, MA
Exercise Physiologist
Founder, Workwell Foundation
Ripon, California

Other Researchers and Clinicians
James N. Baraniuk, MD
Professor of Medicine
Georgetown University
Washington, DC
Lily Chu, MD, MSHS
Independent Researcher
Burlingame, California

Janet L Dafoe, PhD
Child Psychologist in Private Practice
Palo Alto, California

Todd E. Davenport, PT, DPT, MPH, OCS
Professor & Program Director
University of the Pacific
Thomas J. Long School of Pharmacy & Health Sciences
Department of Physical Therapy
Stockton, California

Ronald W. Davis, PhD
Professor of Biochemistry and Genetics
Stanford University
Stanford, California

Lucy Dechene, PhD
Professor of Mathematics (retired)
Fitchburg State University
Fitchburg, Massachusetts

Alan Gurwitt, MD
Clinician in Private Practice (retired)
Associate Clinical Professor
Yale Child Study Center (retired)
New Haven, Connecticut
Associate Clinical Professor
University of Connecticut Department of Psychiatry (retired)
Storrs, Connecticut
Lecturer, Harvard Medical School (retired)
Boston, Massachusetts

Jon D. Kaiser, MD
Clinical Faculty
Department of Medicine
University of California, San Francisco
San Francisco, California

David L. Kaufman, MD
Center for Complex Diseases
Mountain View, California
Member, The ME/CFS Collaborative Research Center at Stanford
Palo Alto, California

Richard Podell, MD, MPH
Clinical Professor, Department of Family Medicine
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Peter C. Rowe, MD
Professor of Pediatrics
Johns Hopkins University School of Medicine
Baltimore, Maryland

J. Mark VanNess, Ph.D.
Professor of Health and Exercise Science
University of the Pacific
Stockton, California
Workwell Foundation
Ripon, California

Sadie Whittaker, PhD
Chief Scientific Officer
Solve ME/CFS Initiative
Los Angeles, California

ME/CFS Patient Organizations
American ME and CFS Society
Massachusetts

Massachusetts ME/CFS & FM Association
Massachusetts

#MEAction
California

Minnesota ME/CFS Alliance
Minnesota

Open Medicine Foundation
California

Pandora Org.
Michigan
Simmaron Research Foundation
Nevada

Solve ME/CFS Initiative
California

Wisconsin ME and CFS Association
Wisconsin

CC:
Assistant Secretary for Health Brett P. Giroir, M.D.